汇宇制药：卡络磺钠注射液获药品注册证书 5月21日晚，汇宇制药（688553）发布公告称，全资子公司四川汇宇海玥医药科技有限公司收到国家药 品监督管理局核准签发的卡络磺钠注射液《药品注册证书》。该药品为化学药品3类，主要用于泌尿系 统、上消化道、呼吸道和妇产科出血疾病的治疗。此次获批视同通过仿制药质量和疗效一致性评价。 资料显示，汇宇制药成立于2010年10月，主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产 和国内外销售。 所属行业：医药生物–化学制药–化学制剂 百合股份：董事拟减持不超过42.4万股公司股份 5月21日晚，百合股份（603102）发布公告称，公司董事王文通计划通过集中竞价方式减持公司股份， 减持数量不超过42.4万股，占公司总股本的0.6625%。减持计划将于公告披露之日起15个交易日后的三 个月内进行。此次减持是基于王文通的个人资金需求。 资料显示，百合股份成立于2005年11月，主营业务是营养保健食品的研发、生产和销售。 所属行业：食品饮料–食品加工–保健品 金固股份：获全球龙头车企美国乘用车车轮项目定点 5月21日晚，金固股份（002488）发布公告称，公司近日收到某全球龙头车 ...

国药现代（600420）公告，全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的 枸橼酸托法替布片《药品注册证书》。枸橼酸托法替布片是一种新型的口服蛋白酪氨酸激酶抑制剂，临 床适用于类风湿关节炎、银屑病关节炎、强直性脊柱炎等。米内网数据库显示，2024年全国公立医疗机 构销售额为人民币4.77亿元。国药容生用于开展枸橼酸托法替布片的累计研发投入约人民币1553.68万 元。本次获得药品注册证书并视同通过一致性评价，将丰富公司抗肿瘤及免疫调节剂领域的制剂产品 群，增强公司在相关用药领域的综合市场竞争力。 ...

Core Viewpoint - The traditional Chinese medicine industry in China is rapidly developing, supported by national policies, with Zhenbaodao (603567.SH) emerging as a leading enterprise in the field, demonstrating stable performance and growth in its financial metrics [1][2][9]. Financial Performance - In 2024, Zhenbaodao achieved an operating income of 2.704 billion yuan and a net profit of 438 million yuan, with the core pharmaceutical industrial revenue reaching 2.376 billion yuan, reflecting a year-on-year growth of 20.23% [1][2][3]. - As of the end of 2024, the company's total assets amounted to 12.713 billion yuan, an increase of 1.98% from the beginning of the year, while the net assets reached 7.801 billion yuan, growing by 3.34% [2][3]. Industry Context - The pharmaceutical manufacturing sector is showing strong resilience amid structural adjustments, with a reported increase of 3.4% in the added value of large-scale pharmaceutical industries in 2024 [2]. - The overall revenue for large-scale pharmaceutical enterprises reached 29.7627 billion yuan, with profits totaling 4.0509 billion yuan, indicating a profit growth rate that outpaces the national industrial average by 2.4 percentage points [2]. Business Operations - Zhenbaodao's pharmaceutical industrial segment is its core business, contributing nearly 90% to its total revenue, with robust manufacturing capabilities across multiple production bases [3]. - The company has established a diverse product portfolio, including raw materials, chemical preparations, traditional Chinese medicine preparations, and biological preparations, supported by ongoing research and development [3]. Innovation and Development - Zhenbaodao is actively fostering new productive forces in the pharmaceutical industry through technological breakthroughs and innovative resource allocation, focusing on the development of innovative and generic drugs [4][5]. - The company has established partnerships with renowned universities and research institutions to enhance the quality standards of traditional Chinese medicine injections and other significant clinical research projects [4]. Social Responsibility and Industry Impact - Zhenbaodao emphasizes its social responsibility as a core strategy, contributing to public health and societal value creation, particularly in the context of increasing chronic disease treatment demands [7][8]. - The company has engaged in various social welfare initiatives, supporting education, culture, and health, thereby enhancing its brand value and long-term growth potential [8]. Recognition and Future Outlook - Zhenbaodao has received numerous accolades, including being listed among the top 100 pharmaceutical companies in China and recognized for its contributions to social responsibility and digital transformation [8][9]. - The ongoing policy support for traditional Chinese medicine is expected to further drive market growth, with Zhenbaodao positioned to leverage these opportunities through innovation and social responsibility [9].

珍宝岛：2024年净利润4.38亿元 医药工业营收同比增长20.23% 智通财经4月29日电，珍宝岛（603567.SH）发布2024年报，公司营收27.04亿元，实现归属于上市公司 股东净利润4.38亿元，医药工业营收同比增长20.23%。公司表示，得益于深化营销渠道改革，产品市场 覆盖率和产品竞争力显著提升。报告期内，公司中药材产业板块稳中有进，"神农洲"中药材电商平台与 线下药市协同互补；新药研发及产品销售进展顺利；公司1.1类创新中药清降和胃颗粒临床试验批准， 枸橼酸托法替布片等10款优质仿制药获批上市；通过深化精细化招商模式，实现市场的"广深透"覆盖， 以终端为单位拉动产品上量。 ...